Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms

Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms
    Personal take on this article: The paper provides a comprehensive set of guidelines for designing antisense oligonucleotides (AONs) with a focus on splice modulation. AONs are tools used to interfere with gene expression by targeting specific mRNA sequences, either to degrade them, block translation, or modify splicing. This study particularly focuses on the latter, using AONs to induce exon skipping in the dystrophin gene, which has therapeutic potential …
more

Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping

Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping
      Personal take on this article: This study evaluates the safety, tolerability, and pharmacokinetics of eteplirsen in boys aged 6 to 48 months with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), is designed to restore dystrophin production. The open-label, dose-escalation trial involved 15 boys divided into two cohorts: one group aged 24 to 48 months and another aged 6 to …
more

Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial

Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial
    Personal take on this article:   This document reports on the findings from a Phase 2b clinical trial that evaluated the effects of vamorolone, a novel steroid, and prednisone on adrenal suppression in boys with Duchenne muscular dystrophy (DMD). The study involved 121 steroid-naive boys aged 4 to under 7 years with genetically confirmed DMD, and assessed adrenal function using morning cortisol levels and ACTH-stimulated cortisol levels. Adrenal …
more

High mobility group box 1 (HMGB1) is a potential disease biomarker in cell and mouse models of Duchenne muscular dystrophy

High mobility group box 1 (HMGB1) is a potential disease biomarker in cell and mouse models of Duchenne muscular dystrophy
    Personal take on this article:   The study investigates the role of high mobility group box protein 1 (HMGB1) as a potential biomarker for Duchenne muscular dystrophy (DMD) by utilizing RNA sequencing in mouse models and human induced pluripotent stem cell (iPSC)-derived skeletal muscle cells. The findings suggest that HMGB1 is elevated in DMD conditions and can be reduced with gene therapy using microdystrophin. This indicates that HMGB1 …
more

Impaired Glucose Tolerance in Adults with Duchenne and Becker Muscular Dystrophy

Personal take on this article: Abstract: This study aimed to evaluate glucose tolerance in adult males with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) using an oral glucose tolerance test (OGTT) and to investigate whether body composition influences glucose response. The study included 28 adults with dystrophinopathy (13 BMD, 15 DMD) and 12 non-dystrophic controls who ingested 75g of glucose. Fingertip blood samples were taken at 30-minute intervals …
more

Recent Posts

Categories

I'd be delighted if you could explore the other sections of my website.

Biochemist Researcher . YouTuber . Medical Laboratory Tech

!I am Ali Nik Akhtar

Personal Website​​​​​​​

If you have any questions or would like to discuss further, please feel free to email me. I would be delighted to get to know you better.

Ready to start a collaboration...​​​​​​​

Contact Me

Nikakhtar422@gmail.com

All rights reserved. This website belongs to Ali Nik Akhtar.